Universal Organ Rescue Technology to Expand the Viable Donor Pool

Targa’s TBM-005 protects donor organs from ischemia-reperfusion injury, making more organs available for life-saving transplantation.

Glowing 3D medical illustration of human lungs in neon blue with a glowing red bronchial tree.

Rescue more organs.
Save more lives.

The organ rescue challenge

+0
patients waiting for organ transplants in the US
+0
people added
to the transplant list, each day
0/day
people die waiting
for an organ

Organ quality, not donor supply, limits transplantation.

After cessation of circulation, warm ischemia triggers cellular injury that continues during recovery, transport and reperfusion.

Donation after Cardiocirculatory Death (DCD) organs face high attrition due to warm ischemia, time-to-recovery constraints and quality concerns.

Current preservation and perfusion systems help evaluate organ function, but they do not actively mitigate ischemic injury that limits the use of DCD and other marginal organs.

Introducing

The organ-conditioning layer for the next generation of transplantation

Targa’s solution

TBM-005 is an ex vivo organ-conditioning additive for preservation and perfusion solutions

Unlike conventional preservation solutions that maintain organ status, TBM-005 actively targets the mechanism responsible for ischemia-reperfusion injury at the cellular level.

Device-agnostic and temperature-flexible, it integrates directly into existing workflows with no new equipment or procedural changes.

  • Added to cold storage and flush solutions at procurement
    (4-10 C)

  • Integrated into warm perfusion media during ex vivo assessment
    (37 C)

  • Compatible with major preservation and perfusion platforms

  • No new hardware or procedural changes required

Applications

Expanding what’s possible in transplant and regenerative science

Lead Clinical Program
Organ Rescue and Transplantation

TBM-005 is our lead ex vivo organ-conditioning additive, designed to improve organ quality during recovery, preservation, and perfusion. The first clinical application is in lung transplantation, with broader potential across liver, heart, and kidney transplantation.

In development
Cell Therapy and Regenerative Medicine

Targa is applying its expertise in cellular protection to develop advanced cell storage and cryopreservation solutions that preserve cell viability and function at ambient and controlled temperatures for cell therapy, and biomanufacturing applications.

Accelerators and Support

Targa partners with preservation and perfusion technology companies, including platforms, devices, and solutions. If our tech could enhance your organ-recovery offering, let’s connect.

Targa partners with preservation and perfusion technology companies, including platforms, devices, and solutions. If our tech could enhance your organ-recovery offering, let’s connect.